UK-based Urathon Europe Ltd has been granted exclusive distribution rights in the UK for a new next-generation Continuous Glucose Monitor (CGM), by Chinese manufacturing giant, Yuwell.  Launching 14^th May 2025, the Yuwell Anytime CGM is set to transform the face of Type II diabetes, one of the biggest drains on the NHS, and the leading cause of serious secondary health complications including renal failure, heart disease, stroke, nerve damage and degrees of sight loss. 

The exponential increase in Type II diabetes far exceeds predictions made just ten years ago.  In addition, the prevalence of the disease in people under 40 years old saw an alarming 40% increase between 2017 and 2023.  Just 8% of the UK population living with diabetes have the incurable Type I diabetes.  The vast majority (90%) of diabetes sufferers have been diagnosed with Type II, which can be managed through lifestyle, and a large percentage of Type II diabetics can successfully go into remission.  In addition, 1 in 9 adults have been diagnosed with prediabetes, and are at risk of going on to develop Type II. 

Tackling Type II diabetes is critical for both the heath of the nation and the health of the NHS.  The use of CGM in people with prediabetes and those with early onset Type II is the cure to the crippling expense this lifestyle-led disease causes.  The new Yuwell Anytime CGM system presents the most affordable solution to this crisis.  It boasts a world-first rechargeable CGM transmitter that lasts two years, slashing the cost compared to alternative CGM systems - the cost of the Yuwell Anytime system therefore represents over 35% less per year to both the NHS and self-funding patients, meaning access to life changing tech to combat Type II diabetes has been revolutionised.  Add to that the slash in cost to the NHS for treatment and medication through prevention and remission, Yuwell Anytime presents the UK with the opportunity to save the NHS £billions per year and positively improve the health of tens of millions of people.

Yuwell Anytime in the UK will spearhead a national public health campaign for CGM tech to be made more widely available at the grassroots of the Diabetes endemic, to combat the growth of the disease and reduce the number of sufferers.  Working in partnership with Leeds University, Brunel University and UCL, and with support from the NIHR, Yuwell Anytime will drive prevention and remission. 

Yuwell Anytime Brand Medical Ambassador and NHS GP, Dr Dawn Harper, MBBS, MRCP, DCH, DFFP, said: “I would love to see this device incorporated into the NHS ‘diabetes prevention programme’. It could help improve the health of millions and save the NHS billions.  Having been diagnosed with diabetes myself, wearing the Yuwell anytime device gave me real time insights into how my body reacts to different foods.  I used the insights to adapt my diet and my HbA1c is now out of the diabetic range.”

Yuwell Anytime Clinical Trial Lead, Dr Andrea Utley, BSc (Hons), PGCE, PhD, said: “Our trial tested the Yuwell Anytime device on a diverse range of individuals with Type II diabetes.  Findings showed a good level of accuracy when compared to a standard finger prick glucose test. In addition the Yuwell device proved to trend well showing excellent performance across a range of glucose levels.”

www.yuwellanytime.co.uk

ALL MEDIA ENQUIRIES PLEASE CONTACT: 

Jo Welch – jo@urathon.com + 44 (0) 7767 416092.